• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Hydrogel Cell Carrier for Fistula Healing

      Hydrogel Cell Carrier for Fistula Healing

      Bottlebrush Particle for Synergistic Drug Combinations

      Bottlebrush Particle for Synergistic Drug Combinations

      Antibacterial Peptide Spray Safe for Use on Wounds

      Antibacterial Peptide Spray Safe for Use on Wounds

      Flexible Sensors Detect Heavy Metals in Sweat

      Flexible Sensors Detect Heavy Metals in Sweat

    • Radiology
      Focused Ultrasound Releases Brain Biomarkers

      Focused Ultrasound Releases Brain Biomarkers

      Tiny Patch for Cardiac Ultrasound Imaging

      Tiny Patch for Cardiac Ultrasound Imaging

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

    • Cardiology
      Tiny Patch for Cardiac Ultrasound Imaging

      Tiny Patch for Cardiac Ultrasound Imaging

      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

      Camera Measures Blood Pressure with Quick Look

      Camera Measures Blood Pressure with Quick Look

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

    • Surgery
      Hydrogel Cell Carrier for Fistula Healing

      Hydrogel Cell Carrier for Fistula Healing

      Antibacterial Peptide Spray Safe for Use on Wounds

      Antibacterial Peptide Spray Safe for Use on Wounds

      Microneedle Bandage for Hemostatic Control

      Microneedle Bandage for Hemostatic Control

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

    • Nanomedicine
      Bottlebrush Particle for Synergistic Drug Combinations

      Bottlebrush Particle for Synergistic Drug Combinations

      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Implanted Magnets for Prosthetic Control

      Implanted Magnets for Prosthetic Control

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Idiopathic Pulmonary Fibrosis Market to 2030 – Market Insights, Epidemiology Data, and Forecast

October 13th, 2020 Report Ocean Releases

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disorder described by interminable, dynamic scarring of the lungs and the pathological sign of normal interstitial pneumonia. The interstitial lung diseases (ILDs) are a heterogeneous collection of parenchymal lung ailments described by shifting degrees of inflammation and fibrosis. A portion of these may occur secondary to a known precipitant, for example, drugs, immune system connective tissue disease, hypersensitivity to breathed in natural antigens, or sarcoidosis, while others, the idiopathic interstitial pneumonia (IIPs), have no recognizable reason. Idiopathic pneumonic fibrosis (IPF) is one of the most forceful types of IIP, described by chronic, progressive fibrosis related with a relentless decrease in lung functionality, progressive respiratory failure, and high mortality. It is a lung issue where there is scarring of the lungs from an obscure reason. It is generally a progressive sickness with a long-term prognosis. The exemplary highlights of the disorder incorporate progressive dyspnea and a non-productive cough. Pneumonic capacity tests ordinarily uncover prohibitive disability and decreased carbon monoxide diffusing limit.

GET SAMPLE COPY @ https://www.reportocean.com/industry-verticals/sample-request?report_id=BWCC44

Idiopathic pulmonary fibrosis: Epidemiology Insights

The Report Ocean will provide insights for epidemiology based on segmentation of Idiopathic pulmonary fibrosis on the basis of following parameters:

  • Total Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
  • Total Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
  • Gender-specific Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
  • Age-specific Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM

Idiopathic pulmonary fibrosis has an estimated prevalence of 13 to 20 per 100,000 people worldwide. About 100,000 people are affected in the United States, and 30,000 to 40,000 new cases are diagnosed each year. Familial pulmonary fibrosis is less common than the sporadic form of the disease.

It was found in studies that an overall prevalence of IPF of 13.2 per 100,000 for women and 20.2 per 100,000 for men. People aged ≥65 years observed IPF rates higher than younger population. Within a period of 10 years, the incidence plateaued while prevalence increased for IPF cases. It was concluded that higher prevalence and incidence rates of IPF are among men and with increasing age, especially after 75 years.

Etiology

The specific etiology for the development of IPF is obscure, however risk factors like exposure to tobacco smoke, wood, metal, viral diseases, dust, a family background of IPF and gastroesophageal reflux have been embroiled. The current hypothesis on the etiology of IPF is that repetitive injury to the alveolar epithelium triggers a cascade of signalling by the immune system prompting fibrosis. A dysregulated reaction to the injury can cause tissue redesigning. Additionally, in IPF patient’s lung epithelium is believed to be broken, and genetically susceptible to atypical reaction to injuries. The onset of IPF is likely brought about by multiple mechanisms.

Market for Idiopathic pulmonary fibrosis

In U.S alone, the prevalent population of Idiopathic Pulmonary Fibrosis is 1,05,544 in 2019. The global Idiopathic pulmonary fibrosis market generated US$1,768.8 million in 2019 and is projected to reach US$2,859.8 million by 2025 and to US$ 4,298.8 million by 2030, growing at a CAGR of 9.4% from 2017 to 2030.

This report forecasts growth of Idiopathic pulmonary fibrosis market at global level and provides an insight of the latest industry in the forecast period 2017-2030. For the current analysis, Report Ocean has segmented the market by drug type.

  • Drug Type
  • MAPK inhibitors
  • tyrosine kinase inhibitors
  • Autotaxin inhibitors

Rising prevalence of IPF is expected to elevate the market. According to the National Institutes of Health (NIH), approximately 40,000 new cases of IPF are diagnosed each year. Furthermore, commercialization of new drugs and rise in cigarette smoking population are some factors which results in escalated demand for IPF treatment and thus leads to market expansion. However, certain factors will hamper industry growth to certain extent. These include the complicated diagnosis and high cost of treatment.

Esbriet (MAPK Inhibitor) by F. Hoffman La Roche and Ofev (Tyrosine Kinase Inhibitor) by Boehringer Ingelheim International GmbH are the only drugs approved by the Food and Drug Administration (FDA) for the treatment of IPF. Both these drugs slow down the death rate in patients with IPF. Among drug class, MAPK Inhibitors (Esbriet) holds the maximum share in the market. Esbriet was the first drug approved in 2011 in Europe for treating mild to moderate IPF and in 2014 in the U.S. for IPF. It is a major drug due to a well-established safety profile. Tyrosine Kinase Inhibitors (OFEV) is expected to grow in market over the forecast period owing to the priority review by the FDA.

North America is the leading region in the IPF treatments market in 2019 due to increasing prices of the drugs, accelerated approvals of the drugs in the U.S. and increasing prevalence of IPF.

Increasing number of IPF cases coupled with rising awareness has stimulated the demand of its treatment. Some of the known players are Genentech, Inc., Boehringer Ingelheim Pharma GmbH and Co. Kg, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc. and others.

Commercialized protocols and products

Esbriet is a prescription medicine used to treat idiopathic pulmonary fibrosis (IPF). Esbriet was originally developed by InterMune Inc., which later merged with Roche. Esbriet is currently marketed and investigated by Genentech (A Roche Company). Esbriet was developed for use by InterMune in the United States, Europe and other countries. It was granted marketing authorization in the European Union (EU) in 2011 for the treatment of adults with mild to moderate IPF.

OFEV is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF), to treat people with a chronic interstitial lung disease in which lung fibrosis continues to worsen and to slow the rate of decline in lung function. It was developed by Boehringer Ingelheim Pharma GmbH and Co. Kg. Ofev’s active ingredient nintedanib is a tyrosine kinase inhibitor (TKI) that inhibits the growth factor receptors involved in the progress of pulmonary fibrosis.

FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF) by FibroGen, Inc. has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.

Have Any Query? Ask Our Experts: https://www.reportocean.com/industry-verticals/sample-request?report_id=BWCC44

Get in Touch with Us:

Report Ocean
Name: Nishi Sharma
Email: sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website: https://www.reportocean.com/

Sign up and submit a press release

Sponsored
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

PT Genie Unveils New Brand Identity Reflecting Company’s Transformation and Focus on the Global Future of AI and Machine Learning in Digital Healthcare

interviews & reviews
Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email